[Role of cardiac resynchronisation in the treatment of cardiac failure].
For 10 years cardiac resynchronisation has seen considerable development, as much on the technological side as at the level of its scientific validation. Several prospective studies have shown the functional benefits of cardiac resynchronisation in a selected population of refractory cardiac failure patients with improvement in symptoms, exercise tolerance and quality of life. Equally, cardiac resynchronisation allows a significant reduction in hospital episodes for cardiac failure and also has a beneficial effect on left ventricular inverse remodelling. Finally, the first results of morbidity/mortality trials are very encouraging with a significant reduction in overall mortality at one year in the COMPANION study with the biventricular defibrillator. However, numerous important, unresolved questions remain such as the problem of non-responders and thus patient selection, or such as the place of cardiac resynchronisation in patients with permanent atrial fibrillation. The choice of the type of implantable prosthesis (pacemaker or biventricular defibrillator) and the choice of the mode of pacing (biventricular or solely left ventricular) are still under discussion. New indications for cardiac resynchronisation could be seen next, for example such as the optimisation of stimulation mode in already paced patients or "systematic" biventricular pacing in patients with a conventional indication for pacing..... In 2004, cardiac resynchronisation must be considered as an effective adjuvant therapy in cardiac failure patients refractory to optimal medical treatment with left ventricular dysfunction and intraventricular conduction disorders.
Leclercq
C
C
Département de cardiologie et maladies vasculaires, centre cardio-pneumologique, hôpital Pontchaillou, Rennes. christophe.leclercq@chu-rennes.fr
Crocq
C
C
Mabo
P
P
Daubert
C
C
D002304:Cardiac Pacing, Artificial; D002986:Clinical Trials as Topic; D017147:Defibrillators, Implantable; D006333:Heart Failure / Q000150:complications* / Q000628:therapy; D006801:Humans; D011379:Prognosis; D017180:Tachycardia, Ventricular / Q000209:etiology / Q000401:mortality / Q000628:therapy*; D018487:Ventricular Dysfunction, Left